XNASBVS
Market cap579mUSD
Jan 14, Last price
8.87USD
1D
-3.17%
1Q
-31.35%
IPO
-48.49%
Name
Bioventus Inc
Chart & Performance
Profile
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 512,345 0.04% | 512,117 18.85% | |||||||
Cost of revenue | 501,477 | 539,584 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 10,868 | (27,467) | |||||||
NOPBT Margin | 2.12% | ||||||||
Operating Taxes | 85 | (50,508) | |||||||
Tax Rate | 0.78% | ||||||||
NOPAT | 10,783 | 23,041 | |||||||
Net income | (156,230) -26.79% | (213,391) -2,326.07% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 778 | 2,470 | |||||||
BB yield | -0.24% | -1.54% | |||||||
Debt | |||||||||
Debt current | 27,848 | 33,056 | |||||||
Long-term debt | 377,571 | 399,807 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 46,084 | 189,289 | |||||||
Net debt | 368,455 | 398,413 | |||||||
Cash flow | |||||||||
Cash from operating activities | 15,344 | (13,537) | |||||||
CAPEX | (7,362) | (11,520) | |||||||
Cash from investing activities | 15,807 | (116,436) | |||||||
Cash from financing activities | (26,653) | 62,076 | |||||||
FCF | (82,355) | 69,326 | |||||||
Balance | |||||||||
Cash | 36,964 | 31,814 | |||||||
Long term investments | 2,636 | ||||||||
Excess cash | 11,347 | 8,844 | |||||||
Stockholders' equity | (273,136) | (141,587) | |||||||
Invested Capital | 935,184 | 1,086,702 | |||||||
ROIC | 1.07% | 2.36% | |||||||
ROCE | 1.64% | ||||||||
EV | |||||||||
Common stock shares outstanding | 62,648 | 61,389 | |||||||
Price | 5.27 101.92% | 2.61 -81.99% | |||||||
Market cap | 330,153 106.05% | 160,226 -81.43% | |||||||
EV | 746,135 | 582,390 | |||||||
EBITDA | 68,233 | 39,336 | |||||||
EV/EBITDA | 10.94 | 14.81 | |||||||
Interest | 40,676 | 25,795 | |||||||
Interest/NOPBT | 374.27% |